CITATION REPORT List of articles citing

D	1	1	• 1	1 C	1 ,	1.
P11	lmonarv	hypertensi	10n diie	to left	neart (ดเรยลรย
	illionidi,	it, por como.	IOII aac	CO TOTE	II Cai c	arocacc

DOI: 10.1183/13993003.01897-2018 European Respiratory Journal, 2019, 53, .

Source: https://exaly.com/paper-pdf/74765934/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
319	Collaborative Cardiology and Pulmonary Management of Pulmonary Hypertension. 2019 , 156, 200-202		2
318	Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?. 2019 , 21, 1057-1061		6
317	Pulmonary hypertension and valvular heart disease. 2019 , 44, 491-501		8
316	Pulmonary hypertension in HFpEF and HFrEF: Pathophysiology, diagnosis, treatment approaches. 2019 , 44, 483-490		9
315	Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure. 2019 , 124, 756-762		9
314	Prognostic Value of the Echocardiographic Probability of Pulmonary Hypertension in Patients with Acute Decompensated Heart Failure. 2019 , 8,		4
313	Noninvasive invasive pressure-flow relationship of the pulmonary circulation: bias and error. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	5
312	Differentiating Precapillary From Postcapillary Pulmonary Hypertension. 2019, 140, 712-714		13
311	Cardiopulmonary interaction in heart or lung disease: physiology, disturbances, and their clinical implications. 2019 , 44, 475-476		О
310	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. 2019 , 38, 1286-1295		22
309	Pulmonary Hypertension Due to Left Heart Disease: an Update. 2019 , 21, 62		8
308	Challenges in pulmonary hypertension associated with left heart disease. 2019 , 17, 461-472		1
307	Prognostic value and diagnostic properties of the diastolic pulmonary pressure gradient in patients with pulmonary hypertension and left heart disease. 2019 , 290, 138-143		9
306	Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. Where to Draw the Line. 2019 , 200, 278-279		3
305	Pulmonary hypertension in left heart disease: The need to continue to explore. 2019 , 288, 132-134		2
304	Right ventricular outflow tract velocity time integral-to-pulmonary artery systolic pressure ratio: a non-invasive metric of pulmonary arterial compliance differs across the spectrum of pulmonary hypertension. 2019 , 9, 2045894019841978		6
303	The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	29

(2020-2019)

302	Proposed new pulmonary hypertension definition: is 4 mm(Hg) worth re-writing medical textbooks?. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	17
301	Intracardiac multimorbidity: assessing right ventricular function in left-sided heart failure through cardiopulmonary exercise testing. 2019 , 17, 331-333		3
300	Disfuncifi ventricular derecha: ¿quĺbpciones tenemos?. 2019 , 18, 46-54		
299	Management of pulmonary arterial hypertension in patients aged over 65 years. 2019 , 21, K29-K36		5
298	Beyond the World Symposium on Pulmonary Hypertension: practical management of pulmonary arterial hypertension and evolving concepts. 2019 , 21, K1-K3		О
297	The Biological Bases of Group 2 Pulmonary Hypertension. 2019 , 20,		11
296	Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. 2019 , 21, 141		27
295	Pulmonary Hypertension with Valvular Heart Disease: When to Treat the Valve Disease and When to Treat the Pulmonary Hypertension. 2019 , 21, 151		7
294	Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension. 2019 , 9, 19572		6
293	Diagnosis of pulmonary hypertension. European Respiratory Journal, 2019, 53,	13.6	175
292	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	1412
291	An overview of the 6th World Symposium on Pulmonary Hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	182
290	Pulmonary hypertension and right ventricular remodeling in HFpEF and HFrEF. 2020 , 25, 85-91		11
29 0 28 9	Pulmonary hypertension and right ventricular remodeling in HFpEF and HFrEF. 2020 , 25, 85-91 Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes: Expanding the Hemodynamic Risk Profile. 2020 , 157, 151-161		11
	Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes: Expanding		
289	Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes: Expanding the Hemodynamic Risk Profile. 2020 , 157, 151-161		12
289	Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes: Expanding the Hemodynamic Risk Profile. 2020 , 157, 151-161 When Pulmonary Hypertension Complicates Heart Failure. 2020 , 16, 53-60 Association Between Right Ventricular Contractile Function and Cardiac Events in Isolated		8

284	Right ventricular-pulmonary arterial uncoupling in mild-to-moderate systemic hypertension. 2020 , 38, 274-281	12
283	Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization: A Prospective Study. 2020 , 13, e007981	9
282	Pharmacologic therapy for pulmonary artery hypertension. 2020 , 35, 643-656	1
281	Pulmonary Hypertension in HFpEF and HFrEF: JACC Review Topic of the Week. 2020 , 76, 1102-1111	26
280	Evaluation and management of pulmonary arterial hypertension. 2020 , 171, 106099	9
279	Pulmonary hypertension associated with left-sided heart failure. 2020 , 35, 610-619	4
278	Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review. 2020 , 10, 20458940209487	80 ²
277	Critical appraisal of the instantaneous end-diastolic pulmonary arterial wedge pressures. 2020 , 7, 4247	1
276	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. 2020 , 39, 1435-1444	24
275	Guidelines for the Treatment of Pulmonary Arterial Hypertension. 2020 , 198, 581-596	16
274	Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization. 2020 , 22, 2228-2237	34
273	Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week. 2020 , 76, 2671-2681	19
272	Prognostic importance of Kidney, Heart and Interstitial lung diseases (KHI triad) in PH: A machine learning study. 2020 , 113, 630-641	Ο
271	Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction. 2020 , 10, 1580-1603	15
270	Narrative review of sleep and pulmonary hypertension. 2020 , 12, S191-S201	1
269	Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension. 2020 , 10, 1659-1674	6
268	Clearing Our Vision for Discerning Precapillary From Postcapillary Pulmonary Hypertension With the OPTICS Risk Score. 2020 , 9, e017685	О
267	Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension. 2020 , 9,	4

266 ATS Core Curriculum 2020. Adult Pulmonary Medicine. **2020**, 1, 416-435

265	Pulmonary Artery Wedge Pressure Respiratory Variation Increases With Sodium Nitroprusside Vasodilator Challenge. 2020 , 26, 1096-1099	
264	Noninvasive Prediction of Elevated Wedge Pressure in Pulmonary Hypertension Patients Without Clear Signs of Left-Sided Heart Disease: External Validation of the OPTICS Risk Score. 2020 , 9, e015992	8
263	Pulmonary arterial hypertension and heart failure with preserved ejection fraction: are they so discordant?. 2020 , 10, 534-545	1
262	The dangerous and contradictory prognostic significance of PVR. 2020 , 7, 2398-2405	2
261	Pulmonary hypertension thresholds: time to lower further?. 2020 , 8, 834-836	O
260	HFpEF, Obesity, and Epicardial Adipose Tissue: Don't Have Your Cake and EAT It, Too. 2020 , 8, 677-680	1
259	Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction. 2020 , 22, 1817-1825	16
258	Current Understanding of Circulating Biomarkers in Pulmonary Hypertension Due to Left Heart Disease. 2020 , 7, 570016	1
257	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. 2020 , 4, 214-225	2
256	Will the Real Pulmonary Pressure Please Stand Up?. 2020 , 17, 1340	
255	Chemerin Added to Endothelin-1 Promotes Rat Pulmonary Artery Smooth Muscle Cell Proliferation and Migration. 2020 , 11, 926	4
254	Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. 2020 , 16, 993-1004	4
253	Echocardiographic Diagnosis of Postcapillary Pulmonary Hypertension: A RIGHT1 Substudy. 2020 , 1, 38-49	1
252	Pulmonary Hypertension: A Brief Guide for Clinicians. 2020 , 95, 1978-1988	38
251	[Current Aspects of Definition and Diagnosis of Pulmonary Hypertension]. 2020 , 74, 847-863	1
250	Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. 2020 , 20, 408	11
249	Association Between Systemic and Pulmonary Vascular Dysfunction in COPD. 2020 , 15, 2037-2047	8

248	Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations. 2020 , 16, 769-785		10
247	Metformin in Pulmonary Hypertension in Left Heart Disease. 2020 , 7, 425		O
246	Pulmonary hypertension in majority countries: opportunities amidst challenges. 2020 , 26, 373-383		1
245	Deep learning to predict elevated pulmonary artery pressure in patients with suspected pulmonary hypertension using standard chest X ray. 2020 , 10, 19311		10
244	Normal and Abnormal Relationships of Pulmonary Artery to Wedge Pressure During Exercise. 2020 , 9, e016339		4
243	Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy. 2020 , 75, 1397-1408		21
242	Pulmonary arterial hypertension with below threshold pulmonary vascular resistance. <i>European Respiratory Journal</i> , 2020 , 56,	3.6	6
241	Exercise and fluid challenge during right heart catheterisation for evaluation of dyspnoea. 2020 , 10,		1
240	Optimizing diastolic pressure gradient assessment. 2020 , 109, 1411-1422		3
239	Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015. 2020 , 13, e005993		4
238	Feature Tracking of Global Longitudinal Strain by Using Cardiovascular MRI Improves Risk Stratification in Heart Failure with Preserved Ejection Fraction. 2020 , 296, 290-298		12
237	The evolution of the : ready for the new decade!. <i>European Respiratory Journal</i> , 2020 , 55,	3.6	
236	Right-sided cardiac disease: no longer the 'dark side of the heart'. 2020 , 22, 1226-1229		О
235	: A New Section of Highlighting Invasive emodynamics. 2020 , 13, e006927		
234	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. 2020, 75, 935-945		10
233	Recurrent but Preventable Pulseless Electrical Activity Arrest: Follow the Guidelines!. 2020 , 13, e006781		1
232	How Closely Do Clinical Trial Participants Resemble "Real-World" Patients with Groups 2 and 3 Pulmonary Hypertension? A Structured Review. 2020 , 17, 779-783		2
231	Updated Perspectives on Pulmonary Hypertension in COPD. 2020 , 15, 1315-1324		9

230	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease: Insights From the PVDOMICS Program. 2020 , 13, e006363	6
229	Exercise intolerance in heart failure: The important role of pulmonary hypertension. 2020 , 105, 1997-2003	1
228	Monitoring pulmonary pressures during long-term continuous-flow left ventricular assist device and fixed pulmonary hypertension: redefining alleged pathophysiological mechanisms?. 2020 , 7, 702-704	3
227	The Heart Failure with Preserved Ejection Fraction Conundrum-Redefining the Problem and Finding Common Ground?. 2020 , 17, 34-42	6
226	Right Heart Failure: A Hemodynamic Review. 2020 , 38, 161-173	6
225	Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis. 2020 , 39, 310-320	12
224	Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center. 2020 , 158, 330-340	7
223	Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics. 2020 , 7, 223-234	5
222	Heart failure in adult congenital heart disease: tetralogy of Fallot. 2020 , 25, 583-598	5
221	Risk Factors for the Development of Functional Tricuspid Regurgitation and Their Population-Attributable Fractions. 2020 , 13, 1643-1651	11
220	Methods to improve the yield of right heart catheterization in pulmonary hypertension. 2020 , 2, 100015	2
219	Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. 2020 , 79, 626-634	11
218	Tips for success in pulmonary hypertension treatment: progress in isolating endothelial cells from pulmonary artery catheters. <i>European Respiratory Journal</i> , 2020 , 55,	
217	Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR). 2020 ,	3
216	A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. 2021 , 159, 791-797	6
215	Sleep-related breathing disorders and pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	8
214	Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database. 2021 , 1586-1597	4
213	Multidimensional assessment and cluster analysis for idiopathic pulmonary arterial hypertension phenotyping. 2021 , 40, 166-167	1

212	Impact of a volume challenge on haemodynamics and prognosis in patients with severe aortic stenosis. 2021 , 8, 508-517	О
211	Management of Pulmonary Arterial Hypertension. 2021 , 15, 2	13
210	Acute Unloading Effects of Sildenafil Enhance Right Ventricular-Pulmonary Artery Coupling in Heart Failure. 2021 , 27, 224-232	5
209	Pulmonary Hypertension Due to Left Heart Disease-A Practical Approach to Diagnosis and Management. 2021 , 37, 572-584	4
208	How to incorporate left atrial strain in the diagnostic algorithm of left ventricular diastolic dysfunction. 2021 , 37, 945-951	2
207	The Differential Impact of the Left Atrial Pressure Components on Pulmonary Arterial Compliance-Resistance Relationship in Heart Failure. 2021 , 27, 277-285	1
206	Experimental Models. 2021, 27-52	
205	Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. European Respiratory Journal, 2021, 57,	7
204	Long-term outcomes of pregnant women with pulmonary hypertension diagnosed by echocardiography: a retrospective cohort study in a single center from China. 2021 , 11, 2045894020966876	4
203	Pulmonary Hypertension in Heart Failure. 2021 , 3, 147	O
202	Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?. 2021, 9,	17
201	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. 2021 , 452-462	
200	Pulmonary arterial hypertension-associated genetic variants in combined post-capillary and pre-capillary pulmonary hypertension: a case report. 2021 , 11, 2045894021996571	
199	Exercise Right Heart Catheterisation in Cardiovascular Diseases: A Guide to Interpretation and Considerations in the Management of Valvular Heart Disease. 2020 , 16, e01	O
198	Systemic Sclerosis and Pulmonary Hypertension: The Great Masquerader. 2021 , 14, e007554	
197	[Differential Diagnosis of Pulmonary Hypertension Using the Example of Collagenosis-associated PAH in the Context of Chronic Lung and Left Heart Disease]. 2021 , 75, 122-137	
196	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. 2021 , 117, 2474-2488	4
195	The predictive value of minute ventilation versus carbon dioxide production in pulmonary hypertension associated with left heart disease. 2021 , 9, 351	1

(2021-2021)

194	Response by Viray et al to Letter Regarding Article, "Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization: A Prospective Study". 2021 , 14, e008304	
193	Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps. 2021 , 10, e017684	2
192	Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. 2021 , 298, 531-549	10
191	Combined pre- and post-capillary pulmonary hypertension: The clinical implications for patients with heart failure. 2021 , 16, e0247987	3
190	The isobaric pulmonary arterial compliance in pulmonary hypertension. 2021 , 7,	1
189	Invasive Hemodynamic and Metabolic Evaluation of HFpEF. 2021 , 23, 1	O
188	NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review. 2021 , 77, 2040-2052	6
187	Correlation of echocardiographic probability of pulmonary hypertension with maternal outcomes in pregnant women with elevated right ventricular systolic pressure. 2021 , 38, 760-766	1
186	Identifying New Targets for Treatment of Pulmonary Hypertension. 2021, 159, 1326-1327	
185	Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease. 2021 , 11, 20458940211001714	1
184	Pulmonary Hypertension. 2021 , 174, ITC49-ITC64	7
183	Impact of targeted pulmonary arterial hypertension therapy in patients with combined post- and precapillary pulmonary hypertension. 2021 , 235, 74-81	2
182	Mild pulmonary hypertension and premature mortality among 154 956 men and women undergoing routine echocardiography. <i>European Respiratory Journal</i> , 2021 ,	13.6 0
181	Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction. 2021 , 8, 2968-2981	4
180	Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction. 2021 , 14, e007555	4
179	Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease. 2021 , 10, e020633	4
178	PTEN as a Therapeutic Target in Pulmonary Hypertension Secondary to Left-heart Failure: Effect of HO-3867 and Supplemental Oxygenation. 2021 , 79, 593-607	2
177	Left ventricular global longitudinal strain predicts elevated cardiac pressures and poor clinical outcomes in patients with non-ischemic dilated cardiomyopathy. 2021 , 19, 21	3

176	Establishing expert consensus for the optimal approach to holistic risk-management in pulmonary arterial hypertension: a Delphi process and narrative review. 2021 , 15, 1493-1503	
175	Preoperative Cardiovascular Assessment of the Renal Transplant Recipient: A Narrative Review. 2021 , 10,	1
174	Exercise right ventricular ejection fraction predicts right ventricular contractile reserve. 2021 , 40, 504-512	2
173	Pulmonary Hypertension - A Distinct Perspective. 2021 , 8, 2349-2362	
172	Recent advancements in pulmonary arterial hypertension and right heart failure research: overview of selected abstracts from ATS2020 and emerging COVID-19 research. 2021 , 11, 20458940211037274	O
171	Under Pressure: Right Heart Catheterization and Provocative Testing for Diagnosing Pulmonary Hypertension. 2021 , 17, 92-100	O
170	Wedge Pressure vs Left Ventricular End-Diastolic Pressure for Pulmonary Hypertension Classification and Prognostication in Severe Aortic Stenosis 2021 , 3, 1428-1437	1
169	Impact of the new definition of pulmonary hypertension according to world symposium of pulmonary hypertension 2018 on diagnosis of post-capillary pulmonary hypertension. 2021 , 335, 105-110	4
168	Pathophysiology of Heart Failure with Preserved Ejection Fraction. 2021 , 17, 327-335	4
167	Pulmonary Hypertension in 2021: Part I-Definition, Classification, Pathophysiology, and Presentation. 2021 ,	6
166	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements. 2021 , 40, 1267-1278	
165	Management of Pulmonary Hypertension in Left Heart Disease. 2021 , 17, 115-123	2
164	Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction. 2021 , 8, 694240	O
163	Risk Factors of Pulmonary Arterial Hypertension and Its Relationship With Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. 2021 , 8, 666431	O
162	Evaluation, Diagnosis, and Classification of Pulmonary Hypertension. 2021 , 17, 86-91	1
161	Noninvasive Hemodynamic Evaluation at Rest in Heart Failure with Preserved Ejection Fraction. 2021 , 17, 423-434	
160	Impact of the new pulmonary hypertension definition on long-term mortality in patients with severe aortic stenosis undergoing valve replacement. 2021 , 44, 1276-1285	1
159	Hemodynamics Prior to Valve Replacement for Severe Aortic Stenosis and Pulmonary Hypertension during Long-Term Follow-Up. 2021 , 10,	O

158	Pulmonary Hypertension in the Context of Heart Failure With Preserved Ejection Fraction. 2021 , 160, 2232-2246	1
157	A predictive model for dilated cardiomyopathy with pulmonary hypertension. 2021 , 8, 4255-4264	1
156	Pulmonale Hypertonie und Rechtsherzinsuffizienz. 2021 , 10, 330-338	
155	Hemodynamics for the Heart Failure Clinician: A State-of-the-Art Review. 2021,	6
154	Pulmonary hypertension phenotypes in patients with systemic sclerosis. 2021, 30,	5
153	Nonresponse to Acute Vasodilator Challenge and Prognosis in Heart Failure With Pulmonary Hypertension. 2021 , 27, 869-876	О
152	The definition of pulmonary hypertension: history, practical implications and current controversies 2021 , 17, 210076	1
151	Right atrial area to left atrial area ratio, a diagnostic and prognostic parameter worth studying in pulmonary hypertension due to left heart disease. 2021 , 338, 238	
150	Improving CT assessment for pulmonary hypertension in patients with severe aortic stenosis, correlation with right heart catheterization. 2021 , 77, 122-129	О
149	CTA pulmonary artery enlargement in patients with severe aortic stenosis: Prognostic impact after TAVR. 2021 , 15, 431-440	2
148	Pulmonary arterial hypertension (PAH) from autopsy study: T-cells, B-cells and mastocytes detection as morphological evidence of immunologically mediated pathogenesis. 2021 , 225, 153552	4
147	Right Heart Pulmonary Circulation Unit Involvement in Left-Sided Heart Failure: Diagnostic, Prognostic, and Therapeutic Implications. 2021 ,	2
146	Hipertensili pulmonar. 2021 , 13, 2359-2370	
145	Decoupling Between Pulmonary Artery Diastolic and Wedge Pressure Following Transcatheter Aortic Valve Replacement. 2021 ,	О
144	Cardiac acoustic biomarkers as surrogate markers to diagnose the phenotypes of pulmonary hypertension: an exploratory study. 2021 , 1	О
143	Group 2 Pulmonary Hypertension: Clinical Features and Treatment. 2022 , 665-677	
142	Group 1 Clinical Features and Treatment. 2022 , 616-632	
141	Cardiac Catheterization in Pulmonary Hypertension. 2022 , 605-615	

140	Echocardiographic measures and subsequent decline in kidney function in older adults: the Atherosclerosis Risk in Communities Study. 2021 ,	1
139	Pulmonary Artery Denervation as an Innovative Treatment for Pulmonary Hypertension With and Without Heart Failure. 2021 , 29, 89-95	O
138	Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up. 2020 , 21, 127	3
137	Pulmonary Hypertension in Heart Failure Patients. 2020 , 6, e05	2
136	Modern Right Heart Catheterization: Beyond Simple Hemodynamics. 2020 , 19, 6-15	7
135	[Functional characterization of patients with isolated post-capillary or combined post-capillary and pre-capillary pulmonary hypertension]. 2021 , 146, e88-e94	О
134	Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension. 2021 , 345, 68-76	3
133	ANTIBIOGRAM STUDY AND ANTIBIOTIC USE EVALUATION USING GYSSEN METHOD IN PATIENTS WITH DIABETIC FOOT. 2017 , 52, 198	O
132	Pulmonary Hypertension in General Cardiology Practice. 2019 , 113, 419-428	2
131	Tools of the Trade: How Do You Perform and Interpret an Exercise Test?. 2019 , 18, 47-55	
130	Pulmonary Hypertension Due to Left Heart Disease©ombine or Not Combined? DPG In or Out? A Practical Approach to the Patient With Suspected Left Heart Disease. 2019 , 18, 87-91	1
129	Predictors of Long-term Outcomes in Patients With Connective Tissue Disease Associated With Pulmonary Arterial Hypertension. 2021 , 27, e371-e377	1
128	Increase in Pulmonary Artery Pressures. 2021 , 101-109	
127	Isolated Postcapillary and Combined Pre- and Postcapillary Pulmonary Hypertension. 2020, 61-70	
126	Pulmonary Hypertension: Overview and Case Study. 2020 , 31, 57-66	1
125	[Problematic aspects of pulmonary hypertension due to left heart disease: focus on combined postcapillary and precapillary pulmonary hypertension]. 2020 , 92, 54-62	2
124	Contrasting haemodynamic effects of exercise and saline infusion in older adults with pulmonary arterial hypertension. 2021 , 7,	О
123	Cardiac catheterization in pulmonary hypertension: doing it right, with a catheter on the left. 2020 , 10, 1718-1724	1

122	Approach to a patient with pulmonary hypertension. 2019 , 16, 478-481	1
121	The haemodynamic assessment of patients with pulmonary arterial hypertension. 2020 , 2020, e202004	
120	Left Heart Disease-Related Pulmonary Hypertension. 2022 , 40, 69-76	3
119	Left atrial unloading with an 8 mm septal cutting balloon to treat postcapillary pulmonary hypertension: a case report. 2021 ,	2
118	Selexipag and the Pulmonary Hypertension Continuum. 2021,	1
117	[Invasive Cardiopulmonary Exercise Testing: A Review]. 2021,	1
116	The haemodynamic assessment of patients with pulmonary arterial hypertension. 2020, 2020, e202004	0
115	2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. 2022 , 26, 4683	9
114	A case of hepatic abscess - the penny dropped!. 2021 , 51, 71-72	
113	Pulmonale Hypertonie. 2022 , 419-438	
113	Pulmonale Hypertonie. 2022, 419-438 Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension 2022, 12, e12028	1
	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI	1
112	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension 2022 , 12, e12028 Utility of Automated Cardiac Chamber Volumetry by Non-Gated CT Pulmonary Angiography for	1
112	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension 2022, 12, e12028 Utility of Automated Cardiac Chamber Volumetry by Non-Gated CT Pulmonary Angiography for Detection of Pulmonary Hypertension Using the 2018 Updated Hemodynamic Definition 2022, Hemodynamic profiles in a series of patients undergoing right heart catheterization. Experience in	1
112 111 110	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension 2022, 12, e12028 Utility of Automated Cardiac Chamber Volumetry by Non-Gated CT Pulmonary Angiography for Detection of Pulmonary Hypertension Using the 2018 Updated Hemodynamic Definition 2022, Hemodynamic profiles in a series of patients undergoing right heart catheterization. Experience in one center of Medellin, Colombia 2022, 92, 53-59 Review of the myelodysplastic syndrome as a cause of group V pulmonary arterial hypertension: an	
112 111 110	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension 2022, 12, e12028 Utility of Automated Cardiac Chamber Volumetry by Non-Gated CT Pulmonary Angiography for Detection of Pulmonary Hypertension Using the 2018 Updated Hemodynamic Definition 2022, Hemodynamic profiles in a series of patients undergoing right heart catheterization. Experience in one center of Medellin, Colombia 2022, 92, 53-59 Review of the myelodysplastic syndrome as a cause of group V pulmonary arterial hypertension: an orphan disease in an orphan pulmonary hypertension group 2022, 101110 Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 2.	1
112 111 110 109 108	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension 2022, 12, e12028 Utility of Automated Cardiac Chamber Volumetry by Non-Gated CT Pulmonary Angiography for Detection of Pulmonary Hypertension Using the 2018 Updated Hemodynamic Definition 2022, Hemodynamic profiles in a series of patients undergoing right heart catheterization. Experience in one center of Medellin, Colombia 2022, 92, 53-59 Review of the myelodysplastic syndrome as a cause of group V pulmonary arterial hypertension: an orphan disease in an orphan pulmonary hypertension group 2022, 101110 Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 2. Echocardiography. 2022, 66, 23-32 the comparative effects of sacubitril/valsartan vs. enalapril on pulmonary hypertension due to	1

104	Magnetic resonance imaging in pulmonary hypertension: an overview of current applications and future perspectives 2022 , 152, w30055	1
103	Influence of Upright Versus Supine Position on Resting and Exercise Hemodynamics in Patients Assessed for Pulmonary Hypertension 2022 , 11, e023839	O
102	OUP accepted manuscript.	6
101	Pulmonary Hypertension and Air Pollution. 2022 , 179-186	
100	Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics 2022 , 22, 56	
99	Connexins may play a critical role in cigarette smoke-induced pulmonary hypertension 2022,	
98	Peak oxygen uptake is a strong prognostic predictor for pulmonary hypertension due to left heart disease 2022 , 22, 137	
97	Lung Biomarkers: a new route for distinguishing pulmonary hypertension due to HFpEF from pulmonary arterial hypertension 2021 ,	
96	Diagnostic accuracy of automated 3D volumetry of cardiac chambers by CT pulmonary angiography for identification of pulmonary hypertension due to left heart disease 2022 , 1	
95	Impact of Esophageal Pressure Measurement on Pulmonary Hypertension Diagnosis in Obese Patients 2022 ,	O
94	Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives 2022 , 15,	3
93	Maternal and fetal outcomes in pregnant women with pulmonary hypertension: The impact of left heart disease. 2022 , 8, 100354	
92	Pulmonale Hypertonie: Differenzialdiagnostik und therapeutische Konsequenzen. 2021 , 17, 317-333	
91	Therapeutic approaches to improve pulmonary arterial load and right ventricular pulmonary arterial coupling. 2022 , 935-958	
90	Der Rechtsherzkatheter - Schritt ffl Schritt. 2022 , 76,	
89	Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF 2022 , 23,	0
88	Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure 2022 , 1	2
87	When Pulmonary Hypertension Complicates Heart Failure 2022 , 40, 191-198	O

86	Table_1.DOCX. 2020 ,	
85	Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension 2022 , 9, 838898	
84	Differentiating pulmonary hypertension associated with protein kinase inhibitors. 2022, 12,	
83	Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry 2022 , e024969	7
82	Right Heart Catheterization and Pulmonary Hemodynamics. 2022, 503-511	
81	Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland 2022 , 9,	0
80	Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension 2022 ,	1
79	The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension 2022 , 17, e0265059	1
78	Pulmonary Vasculature Responsiveness to Phosphodiesterase-5A Inhibition in Heart Failure With Reduced Ejection Fraction: Possible Role of Plasma Potassium. 2022 , 9,	
77	Histopathological Findings of Pulmonary Hypertension With Elevated Pulmonary Arterial Wedge Pressure in Hereditary Hemorrhagic Telangiectasia. 2022 ,	
76	Combined pre- and post-capillary pulmonary hypertension in left heart disease.	2
75	THE ROLE OF EXERCISE RIGHT HEART CATHETERIZATION TO GUIDE PULMONARY HYPERTENSION THERAPY IN OLDER ADULTS.	
74	Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. 2022 , 9, 151-160	1
73	Decreased Peak Left Atrial Longitudinal Strain Is Associated with Persistent Pulmonary Hypertension Associated with Left Heart Disease. 2022 , 11, 3510	
72	ISHLT CONSENSUS STATEMENT: Peri-operative Management of Patients with Pulmonary Hypertension and Right Heart Failure Undergoing Surgery. 2022 ,	0
71	Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. 2022 , 9,	
70	Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside. 2022 , 145, 107022	О
69	Invasive Cardiopulmonary Hemodynamic Assessment in Patients with Advanced Heart Failure: How to Interpret?. 2022 , 2, 165-172	

68	The future of heart failure with preserved ejection fraction.	O
67	Update in approaches to pulmonary hypertension because of left heart disease. Publish Ahead of Print,	O
66	Emerging phenotypes of pulmonary hypertension associated with COPD a field guide. Publish Ahead of Print,	
65	Hemodynamic Responses to Provocative Maneuvers during Right Heart Catheterization.	
64	Are you coupled? Hemodynamic phenotyping in pulmonary hypertension.	0
63	Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association.	1
62	First-pass perfusion cardiovascular magnetic resonance parameters as surrogate markers for left ventricular diastolic dysfunction: a validation against cardiac catheterization.	О
61	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879	18
60	Corrected MRI Pulmonary Transit Time for Identification of Combined Precapillary and Postcapillary Pulmonary Hypertension in Patients With Left Heart Disease.	
59	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.	58
58	Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: Insights from the MEMS-HF study.	3
57	Pulmonary Hypertension Definition, Classification and Epidemiology in Asia. 2022,	О
56	The prevalence and survival of pulmonary hypertension due to left heart failure: A retrospective analysis of a multicenter prospective cohort study. 9,	
55	Impact of borderline pulmonary hypertension due to left heart failure on mortality in a multicenter registry study: A 3-year survivorship analysis. 9,	
54	Right Heart Catheterization (RHC): A comprehensive review of provocation tests and hepatic hemodynamics in patients with pulmonary hypertension (PH) 2022 , 101351	0
53	Higher plasma IL-6 and PTX3 are associated with worse survival in left heart failure with pulmonary hypertension. 2022 , 20, 100190	
52	Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. 2022 , 15, 1024	
51	Coronary perfusion pressure is associated with adverse outcomes in advanced heart failure. 02676591221	1186

50	Molecular Pathways in Pulmonary Arterial Hypertension. 2022 , 23, 10001	1
49	Editorial for Corrected MRI Pulmonary Transit Time for Identification of Combined Pre and PostCapillary Pulmonary Hypertension in Patients With Left Heart Disease	O
48	Utilidad de la ergoespirometr en el diagnatico precoz de hipertensia pulmonar en pacientes con esclerodermia. 2022,	O
47	Clinical Characteristics of Patients Undergoing Right Heart Catheterizations in Community Hospitals. 2022 , 11,	1
46	Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure. 2022, 19, 364-374	O
45	Pregnant outcomes of critically ill pregnant patients with pulmonary hypertension: A multicenter retrospective study. 9,	O
44	Case report: The impact of percutaneous atrial septal defect closure in pulmonary hypertension with co-existing cor triatriatum sinister and multiple cardiac comorbidities. 9,	0
43	A Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension. 2022 , 162, 511-513	O
42	Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.	0
41	Der Rechtsherzkatheter - Schritt f Schritt. 2022 , 18, 225-232	O
41 40	Der Rechtsherzkatheter - Schritt fli Schritt. 2022, 18, 225-232 An updated meta-analysis of hemodynamics markers of prognosis in patients with pulmonary hypertension due to left heart disease	0
	An updated meta-analysis of hemodynamics markers of prognosis in patients with pulmonary	
40	An updated meta-analysis of hemodynamics markers of prognosis in patients with pulmonary hypertension due to left heart disease	0
40	An updated meta-analysis of hemodynamics markers of prognosis in patients with pulmonary hypertension due to left heart disease Hemodynamic Assessment in Heart Failure with Preserved Ejection Fraction. 2022, 40, 459-472	0
4º 39 38	An updated meta-analysis of hemodynamics markers of prognosis in patients with pulmonary hypertension due to left heart disease Hemodynamic Assessment in Heart Failure with Preserved Ejection Fraction. 2022, 40, 459-472 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction. 2022, 40, 533-540	0 0
39 38 37	An updated meta-analysis of hemodynamics markers of prognosis in patients with pulmonary hypertension due to left heart disease Hemodynamic Assessment in Heart Failure with Preserved Ejection Fraction. 2022, 40, 459-472 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction. 2022, 40, 533-540 76-Year-Old Woman With Hemoptysis. 2022, Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling	o o o
39 38 37 36	An updated meta-analysis of hemodynamics markers of prognosis in patients with pulmonary hypertension due to left heart disease Hemodynamic Assessment in Heart Failure with Preserved Ejection Fraction. 2022, 40, 459-472 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction. 2022, 40, 533-540 76-Year-Old Woman With Hemoptysis. 2022, Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice. 2022, Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World	O O O

32	Heart diseases, hypertension and effects of antihypertensive medications: Is hypertension a true risk factor of heart diseases?. 10,	O
31	Funktionelle Charakterisierung von Patienten mit isoliert postkapillær oder kombiniert post- und pr¶apillær pulmonaler Hypertonie. 2022 , 76, 689-696	О
30	A Sinister Presentation. 2022 , 19, 1925-1929	O
29	Pathophysiological Bases of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction and Implications for Management. 2022 , 2, 296-298	o
28	Mildly Elevated Pulmonary Hypertension. 2023 , 19, 1-9	0
27	How to Treat Right Heart Failure. Tips for Clinicians in Everyday Practice. 2023 , 19, 125-135	o
26	Left Heart Disease Phenotype in Elderly Patients with Pulmonary Arterial Hypertension: Insights from the Italian PATRIARCA Registry. 2022 , 11, 7136	0
25	B adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.	2
24	Diagnosis and management of pulmonary arterial hypertension. 2022, 18, 220168	0
23	Lung diffusion capacity correlates with pre-implant pulmonary hypertension and predicts outcome after LVAD implantation.	О
22	Phenotype of patients with pulmonary hypertension due to left heart disease: features of pathophysiology and differential diagnosis. 2023 , 11, 118-129	O
21	2022 ESC/ERS-Leitlinien zur Diagnostik und Therapie der pulmonalen Hypertonie.	О
20	Pulmonary veno-occlusive disease in Sjogren's syndrome: a case report. 2023 , 23,	O
19	Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?.	O
18	Pulmonary Hypertension Phenotype Can Be Identified in Heart Failure with Reduced Ejection Fraction Using Echocardiographic Assessment of Pulmonary Artery Pressure with Supportive Use of Pressure Reflection Variables. 2023 ,	0
17	Concomitant Transcatheter Edge-to-Edge Treatment of Secondary Tricuspid and Mitral Regurgitation. 2023 , 16, 127-139	1
16	Prevalence of pulmonary hypertension in aortic regurgitation and its influence on outcomes. heartjnl-20	22-322187
15	Effect of preoperative pulmonary artery pressure on the prognosis of end-stage heart failure patients after heart transplantation. 2023 , 18,	o

CITATION REPORT

14	A review of cardio-pulmonary microvascular dysfunction in pulmonary hypertension. 2023, 26, 100255	0
13	Pulmonary Vascular Reverse Remodeling After Left Ventricular Assist Device Implantation in Patients With Pulmonary Hypertension. 2023 , 69, 151-158	O
12	Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction.	О
11	The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges. Volume 19, 103-126	Ο
10	The First Pulmonary Hypertension Registry in the United Arab Emirates (UAEPH): Clinical Characteristics, Hemodynamic Parameters with Focus on Treatment and Outcomes for Patients with Group 1-PH. 2023 , 12, 1996	O
9	Redo mitral valve replacement in an adult atrioventricular septal defect heart with severe pulmonary hypertension: A case study.	Ο
8	Pulmonary hypertension in patients with multiple myeloma: A comprehensive review. 2023, 13,	0
7	Role of cardiopulmonary exercise test in early diagnosis of pulmonary hypertension in scleroderma patients. 2023 , 160, 283-288	O
6	Pulmonary Hypertension in Heart Failure. 2023 , 225-236	0
5	Prevalence of pulmonary hypertension in aortic stenosis and its influence on outcomes. heartjnl-2022-322184	10
4	Pulmonary Hypertension in Orphan Lung Diseases. 2023 , 715-733	О
3	Safety and effectiveness of standardized exercise training in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (TRAIN-HFpEF-PH): study protocol for a randomized controlled multicenter trial. 2023 , 24,	O
2	Hemodynamic characteristics in patients with pulmonary hypertension and chronic obstructive pulmonary disease: A retrospective monocentric cohort study. 2023 , 83, 101008	O
1	Pulmonary Vascular Disease in Veterans with Post-Deployment Respiratory Syndrome.	O